Wednesday, June 08, 2016 8:38:46 AM
CAMBRIDGE, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company’s lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
The poster, which summarizes topline results for a randomized, double-blind, three-arm, parallel group, single-dose study that was designed jointly by Momenta, Baxalta, and Quintiles, Inc., met its primary endpoint late last year. Pharmacokinetic, safety, and immunogenicity data for M923 compared with U.S.- and EU-sourced HUMIRA reference products will be presented.
Poster Presentation Details
Poster #FRI0182: A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (a Proposed Biosimilar to Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects
Presentation Date/Time: Friday, June 10, 2016; 11:45 a.m. local time
Presenter: Jan Hillson, MD; Vice President, Clinical Research, Momenta Pharmaceuticals
About M923, a proposed biosimilar of HUMIRA® (adalimumab)
M923 is developed in collaboration by Baxalta Incorporated, now part of Shire plc, and Momenta Pharmaceuticals. HUMIRA, the largest selling therapeutic on the market today, is a significant intervention for patients with autoimmune/inflammatory diseases. Adalimumab is used to treat many such conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.
http://ir.momentapharma.com/releasedetail.cfm?ReleaseID=974806
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM